251 related articles for article (PubMed ID: 25352398)
21. An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma.
Temam S; Spicer J; Farzaneh F; Soria JC; Oppenheim D; McGurk M; Hollebecque A; Sarini J; Hussain K; Soehrman Brossard S; Manenti L; Evers S; Delmar P; Di Scala L; Mancao C; Feuerhake F; Andries L; Ott MG; Passioukov A; Delord JP
Ann Oncol; 2017 Nov; 28(11):2827-2835. PubMed ID: 28950289
[TBL] [Abstract][Full Text] [Related]
22. Tumor-Specific Antibody, Cetuximab, Enhances the
Jin WJ; Erbe AK; Schwarz CN; Jaquish AA; Anderson BR; Sriramaneni RN; Jagodinsky JC; Bates AM; Clark PA; Le T; Lan KH; Chen Y; Kim K; Morris ZS
Front Immunol; 2020; 11():591139. PubMed ID: 33281820
[TBL] [Abstract][Full Text] [Related]
23. Protective effects of interferon-gamma on squamous-cell carcinoma of head and neck targets in antibody-dependent cellular cytotoxicity mediated by human natural killer cells.
Sung MW; Johnson JT; Van Dongen G; Whiteside TL
Int J Cancer; 1996 May; 66(3):393-9. PubMed ID: 8621263
[TBL] [Abstract][Full Text] [Related]
24. Relationship Between EGFR Expression in Oral Cancer Cell Lines and Cetuximab Antibody-dependent Cell-mediated Cytotoxicity.
Nakamura H; Tamaki S; Yagyuu T; Yamakawa N; Hatake K; Kirita T
Anticancer Res; 2019 Mar; 39(3):1275-1282. PubMed ID: 30842158
[TBL] [Abstract][Full Text] [Related]
25. NK cell dysfunction with down-regulated CD16 and up-regulated CD56 molecules in patients with esophageal squamous cell carcinoma.
Watanabe M; Kono K; Kawaguchi Y; Mizukami Y; Mimura K; Maruyama T; Izawa S; Fujii H
Dis Esophagus; 2010 Nov; 23(8):675-81. PubMed ID: 20545975
[TBL] [Abstract][Full Text] [Related]
26. CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.
Jie HB; Schuler PJ; Lee SC; Srivastava RM; Argiris A; Ferrone S; Whiteside TL; Ferris RL
Cancer Res; 2015 Jun; 75(11):2200-10. PubMed ID: 25832655
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy.
Bedi A; Chang X; Noonan K; Pham V; Bedi R; Fertig EJ; Considine M; Califano JA; Borrello I; Chung CH; Sidransky D; Ravi R
Mol Cancer Ther; 2012 Nov; 11(11):2429-39. PubMed ID: 22927667
[TBL] [Abstract][Full Text] [Related]
28. Production by human squamous cell carcinoma of a factor inducing activation and proliferation of immune cells.
Hirabayashi H; Yasumura S; Lin WC; Amoscato A; Johnson JT; Herberman RB; Whiteside TL
Arch Otolaryngol Head Neck Surg; 1995 Mar; 121(3):285-92. PubMed ID: 7873144
[TBL] [Abstract][Full Text] [Related]
29. Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma.
Faden DL; Concha-Benavente F; Chakka AB; McMichael EL; Chandran U; Ferris RL
Head Neck; 2019 Aug; 41(8):2591-2601. PubMed ID: 30828910
[TBL] [Abstract][Full Text] [Related]
30. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
Kondo N; Tsukuda M; Taguchi T; Nakazaki K; Sakakibara A; Takahashi H; Toth G; Nishimura G
Cancer Sci; 2011 Sep; 102(9):1717-23. PubMed ID: 21631644
[TBL] [Abstract][Full Text] [Related]
31. Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K
Braig F; Kriegs M; Voigtlaender M; Habel B; Grob T; Biskup K; Blanchard V; Sack M; Thalhammer A; Ben Batalla I; Braren I; Laban S; Danielczyk A; Goletz S; Jakubowicz E; Märkl B; Trepel M; Knecht R; Riecken K; Fehse B; Loges S; Bokemeyer C; Binder M
Cancer Res; 2017 Mar; 77(5):1188-1199. PubMed ID: 28031227
[TBL] [Abstract][Full Text] [Related]
32. STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV
Lu S; Concha-Benavente F; Shayan G; Srivastava RM; Gibson SP; Wang L; Gooding WE; Ferris RL
Oral Oncol; 2018 Mar; 78():186-193. PubMed ID: 29496049
[TBL] [Abstract][Full Text] [Related]
33. Anti-epidermal growth factor receptor (EGFR) antibodies overcome resistance of ovarian cancer cells to targeted therapy and natural cytotoxicity.
Gottschalk N; Kimmig R; Lang S; Singh M; Brandau S
Int J Mol Sci; 2012; 13(9):12000-12016. PubMed ID: 23109896
[TBL] [Abstract][Full Text] [Related]
34. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma.
Kawaguchi Y; Kono K; Mimura K; Sugai H; Akaike H; Fujii H
Int J Cancer; 2007 Feb; 120(4):781-7. PubMed ID: 17096332
[TBL] [Abstract][Full Text] [Related]
35. Natural killer (NK) cells as effectors of antibody-dependent cytotoxicity with chimeric antibodies reactive with human squamous-cell carcinomas of the head and neck.
Sung MW; Yasumura S; Johnson JT; Van Dongen GA; Whiteside TL
Int J Cancer; 1995 Jun; 61(6):864-72. PubMed ID: 7790123
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade.
Roberti MP; Juliá EP; Rocca YS; Amat M; Bravo AI; Loza J; Coló F; Loza CM; Fabiano V; Maino M; Podhorzer A; Fainboim L; Barrio MM; Mordoh J; Levy EM
Eur J Immunol; 2015 May; 45(5):1560-9. PubMed ID: 25726929
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma.
Watanabe M; Kono K; Kawaguchi Y; Mizukami Y; Mimura K; Maruyama T; Fujii H
Br J Cancer; 2010 Feb; 102(3):520-9. PubMed ID: 20029417
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro.
Sawatani Y; Komiyama Y; Nakashiro KI; Uchida D; Fukumoto C; Shimura M; Hasegawa T; Kamimura R; Hitomi-Koide M; Hyodo T; Kawamata H
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878053
[TBL] [Abstract][Full Text] [Related]
39. A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer.
Bertino EM; McMichael EL; Mo X; Trikha P; Davis M; Paul B; Grever M; Carson WE; Otterson GA
Mol Cancer Ther; 2016 Sep; 15(9):2244-50. PubMed ID: 27458141
[TBL] [Abstract][Full Text] [Related]
40. Does dexamethasone inhibit anticancer activity of cetuximab in squamous cell carcinoma cell lines of the head and neck?
Wagenblast J; Baghi M; Mörtel S; Hirth D; Thron L; Arnoldner C; Gstöttner W; May A; Hambek M
Oncol Rep; 2009 Jul; 22(1):171-6. PubMed ID: 19513520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
